These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 2391071)

  • 1. Comprehensive study of the biliary bile acid composition of patients with cystic fibrosis and associated liver disease before and after UDCA administration.
    Nakagawa M; Colombo C; Setchell KD
    Hepatology; 1990 Aug; 12(2):322-34. PubMed ID: 2391071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis.
    Colombo C; Setchell KD; Podda M; Crosignani A; Roda A; Curcio L; Ronchi M; Giunta A
    J Pediatr; 1990 Sep; 117(3):482-9. PubMed ID: 2391610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: a dose-response study.
    Colombo C; Crosignani A; Assaisso M; Battezzati PM; Podda M; Giunta A; Zimmer-Nechemias L; Setchell KD
    Hepatology; 1992 Oct; 16(4):924-30. PubMed ID: 1398498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bile acid conjugation in early stage cholestatic liver disease before and during treatment with ursodeoxycholic acid.
    Fracchia M; Setchell KD; Crosignani A; Podda M; O'Connell N; Ferraris R; Hofmann AF; Galatola G
    Clin Chim Acta; 1996 Apr; 248(2):175-85. PubMed ID: 8740581
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease.
    Lindblad A; Glaumann H; Strandvik B
    Hepatology; 1998 Jan; 27(1):166-74. PubMed ID: 9425933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease.
    Colombo C; Crosignani A; Alicandro G; Zhang W; Biffi A; Motta V; Corti F; Setchell KDR
    J Pediatr; 2016 Oct; 177():59-65.e1. PubMed ID: 27297203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum bile acids and ursodeoxycholic acid treatment in cystic fibrosis-related liver disease.
    O'Brien SM; Campbell GR; Burke AF; Maguire OC; Rowlands BJ; FitzGerald MX; Hegarty JE
    Eur J Gastroenterol Hepatol; 1996 May; 8(5):477-83. PubMed ID: 8804877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile acid glycine and taurine conjugates in serum of patients with primary biliary cirrhosis: effect of ursodeoxycholic treatment.
    Chretien Y; Poupon R; Gherardt MF; Chazouilleres O; Labbe D; Myara A; Trivin F
    Gut; 1989 Aug; 30(8):1110-5. PubMed ID: 2767508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biliary bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid.
    Combes B; Carithers RL; Maddrey WC; Munoz S; Garcia-Tsao G; Bonner GF; Boyer JL; Luketic VA; Shiffman ML; Peters MG; White H; Zetterman RK; Risser R; Rossi SS; Hofmann AF
    Hepatology; 1999 Jun; 29(6):1649-54. PubMed ID: 10347103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of ursodeoxycholic acid on serum liver enzymes and bile acid metabolism in chronic active hepatitis: a dose-response study.
    Crosignani A; Battezzati PM; Setchell KD; Camisasca M; Bertolini E; Roda A; Zuin M; Podda M
    Hepatology; 1991 Feb; 13(2):339-44. PubMed ID: 1671665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of serum and urinary bile acids in patients with primary biliary cirrhosis by gas-liquid chromatography-mass spectrometry: effect of ursodeoxycholic acid treatment.
    Batta AK; Arora R; Salen G; Tint GS; Eskreis D; Katz S
    J Lipid Res; 1989 Dec; 30(12):1953-62. PubMed ID: 2621422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis.
    Stiehl A; Rudolph G; Raedsch R; Möller B; Hopf U; Lotterer E; Bircher J; Fölsch U; Klaus J; Endele R
    Hepatology; 1990 Sep; 12(3 Pt 1):492-7. PubMed ID: 2401455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of ursodeoxycholic acid on biliary bile acid composition in patients with cholesterol gallstone.
    Kanazawa Y; Koizumi M; Hirakawa H; Endo K; Yoshida S; Miyakawa T; Konno Y; Goto Y; Goto J; Nambara T
    Tohoku J Exp Med; 1982 Mar; 136(3):235-49. PubMed ID: 7071843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis.
    Podda M; Ghezzi C; Battezzati PM; Crosignani A; Zuin M; Roda A
    Gastroenterology; 1990 Apr; 98(4):1044-50. PubMed ID: 1968871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differing effects of nor-ursodeoxycholic or ursodeoxycholic acid on hepatic histology and bile acid metabolism in the rabbit.
    Cohen BI; Hofmann AF; Mosbach EH; Stenger RJ; Rothschild MA; Hagey LR; Yoon YB
    Gastroenterology; 1986 Jul; 91(1):189-97. PubMed ID: 3710068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration.
    Crosignani A; Podda M; Battezzati PM; Bertolini E; Zuin M; Watson D; Setchell KD
    Hepatology; 1991 Dec; 14(6):1000-7. PubMed ID: 1959845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intestinal absorption and biliary secretion of ursodeoxycholic acid and its taurine conjugate.
    Rudolph G; Kloeters-Plachky P; Sauer P; Stiehl A
    Eur J Clin Invest; 2002 Aug; 32(8):575-80. PubMed ID: 12190957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis.
    Colombo C; Battezzati PM; Podda M; Bettinardi N; Giunta A
    Hepatology; 1996 Jun; 23(6):1484-90. PubMed ID: 8675168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: a randomized, placebo-controlled, crossover trial.
    Merli M; Bertasi S; Servi R; Diamanti S; Martino F; De Santis A; Goffredo F; Quattrucci S; Antonelli M; Angelico M
    J Pediatr Gastroenterol Nutr; 1994 Aug; 19(2):198-203. PubMed ID: 7815243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous ursodeoxycholic acid and cholic acid in liver disease due to cystic fibrosis.
    Smith JL; Lewindon PJ; Hoskins AC; Pereira TN; Setchell KD; O'Connell NC; Shepherd RW; Ramm GA
    Hepatology; 2004 Jun; 39(6):1673-82. PubMed ID: 15185309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.